The estimated Net Worth of Jean Francois Formela is at least $247 Million dollars as of 28 June 2021. Jean Formela owns over 553,376 units of Intellia Therapeutics Inc stock worth over $202,400 and over the last 22 years he sold NTLA stock worth over $246,695,773. In addition, he makes $179,497 as Independent Director at Intellia Therapeutics Inc.
Jean has made over 31 trades of the Intellia Therapeutics Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently he sold 2,055,063 units of NTLA stock worth $78,092,394 on 14 September 2021.
The largest trade he's ever made was selling 2,055,063 units of Intellia Therapeutics Inc stock on 14 September 2021 worth over $78,092,394. On average, Jean trades about 100,696 units every 94 days since 2003. As of 28 June 2021 he still owns at least 10,000 units of Intellia Therapeutics Inc stock.
You can see the complete history of Jean Formela stock trades at the bottom of the page.
Dr. Jean-Francois Formela M.D. serves as Independent Director of the Company since May 2014. Dr. Formela is currently a partner at Atlas Venture, a life sciences-focused venture capital firm, which he joined in 1993. Prior to joining Atlas Venture, Dr. Formela served as a senior director of medical marketing and scientific affairs at Schering-Plough Corporation, a pharmaceutical company which since merged with Merck & Co., Inc. (“Merck”). Dr. Formela began his career as a physician practicing emergency medicine at Necker University Hospital in Paris. Dr. Formela currently serves on the board of directors of Translate Bio, Inc., and Spero Therapeutics. Within the last five years, he also served on the board of directors of Egalet Corporation (now known as Zyla Life Sciences) until April 2017. Dr. Formela currently serves on the board of directors of various private biotechnology and healthcare companies. Dr. Formela is a member of the Partners Healthcare Innovation Advisory Board and a former trustee of the Boston Institute of Contemporary Art. He also is a member of the MGH Research Institute advisory council. He received his M.D. from the Paris University School of Medicine and his M.B.A. from Columbia University.
As the Independent Director of Intellia Therapeutics Inc, the total compensation of Jean Formela at Intellia Therapeutics Inc is $179,497. There are 15 executives at Intellia Therapeutics Inc getting paid more, with Laura Sepp-Lorenzino having the highest compensation of $1,762,490.
Jean Formela is 63, he's been the Independent Director of Intellia Therapeutics Inc since 2014. There are 3 older and 16 younger executives at Intellia Therapeutics Inc. The oldest executive at Intellia Therapeutics Inc is Jesse Goodman, 68, who is the Independent Director.
Jean's mailing address filed with the SEC is C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET; SUITE 130, CAMBRIDGE, MA, 02139.
Over the last 9 years, insiders at Intellia Therapeutics Inc have traded over $210,567,884 worth of Intellia Therapeutics Inc stock and bought 1,285,277 units worth $23,117,886 . The most active insiders traders include Carl L Gordon, Jean Francois Formela, and Bros. Advisors Lpbaker Feli.... On average, Intellia Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $1,357,638. The most recent stock trade was executed by Eliana Clark on 1 July 2024, trading 405 units of NTLA stock currently worth $9,287.
intellia therapeutic’s core mission is to develop curative medicines, utilizing the promise of the crispr/cas9 gene editing technology. the development of crispr/cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. adapted from a natural cellular process, crispr/cas9 permits the editing of any gene in any organism with unprecedented simplicity and flexibility. the incredible potential of this technology for treating human genetic disease inspired a group of life science veterans to create intellia therapeutics. intellia was founded in 2014 by caribou biosciences and atlas venture, along with a consortium of scientists who have helped define the space. intellia therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of crispr/cas9 technology for human therapeutic use. intellia has built an experienced team of individuals to meet the challenges of bringing crispr/cas9 therapeutics to the
Intellia Therapeutics Inc executives and other stock owners filed with the SEC include: